Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, P.O. Box 35516, Mansoura, Egypt.
Department of Pharmacology and Biochemistry, Faculty of Pharmaceutical Sciences & Pharmaceutical Industries, Future University in Egypt, 12311 Cairo, Egypt.
Bioorg Chem. 2019 Jul;88:102923. doi: 10.1016/j.bioorg.2019.102923. Epub 2019 Apr 10.
A new series of 6-substituted amido, azo or thioureido-quinazolin-4(3H)-one was synthesized and tested for their in-vitro antitumor activity. Compounds 21, 53 and 60 showed broad spectrum antitumor activity with average IC values of 6.7, 7.6 and 9.1 μM, respectively compared with methotrexate (1, IC 19.26 μM). As an attempt to reveal the mechanism of the antitumor potency, cell cycle analysis and DHFR inhibition were performed. Compounds 59 and 61 induced their cytotoxicity in Hela (IC 10.6 μM) and HCT-116 (IC 15.5 μM) cell lines, respectively through Pre-G1 apoptosis, inhibiting cell growth at G2-M phase. Compounds 29, 33, 59 and 61 showed DHFR inhibitory potency at IC 0.2, 0.2, 0.3 and 0.3 μM, respectively. The active DHFR inhibitors showed high affinity binding toward the amino acid residues Thr56, Ser59 and Ser118. The active compounds obeyed Lipinski's rule of five and could be used as template model for further optimization.
我们合成了一系列 6 位取代的酰胺、偶氮或硫脲基-喹唑啉-4(3H)-酮,并测试了它们的体外抗肿瘤活性。与甲氨蝶呤(1,IC 19.26 μM)相比,化合物 21、53 和 60 表现出广谱抗肿瘤活性,平均 IC 值分别为 6.7、7.6 和 9.1 μM。作为揭示抗肿瘤效力机制的尝试,我们进行了细胞周期分析和 DHFR 抑制实验。化合物 59 和 61 分别通过 Pre-G1 凋亡,在 Hela(IC 10.6 μM)和 HCT-116(IC 15.5 μM)细胞系中诱导细胞毒性,抑制 G2-M 期细胞生长。化合物 29、33、59 和 61 对 DHFR 的抑制活性分别为 IC 0.2、0.2、0.3 和 0.3 μM。活性 DHFR 抑制剂与 Thr56、Ser59 和 Ser118 氨基酸残基具有高亲和力结合。这些活性化合物符合 Lipinski 的五规则,可作为进一步优化的模板模型。